If you’re developing a generic drug, launching a bioequivalence study, or building an ANDA submission, you’ll eventually need to source a Reference Listed Drug — and getting that sourcing decision wrong can delay a study by weeks or invalidate results outright. Here’s what an RLD actually is, why it matters, and what separates a reliable sourcing partner from a risky one.
What Is a Reference Listed Drug (RLD)?
A Reference Listed Drug is the approved drug product that a generic manufacturer must show bioequivalence against in order to gain regulatory approval. In the U.S., the FDA designates RLDs in the Orange Book (Approved Drug Products with Therapeutic Equivalence Evaluations) — the RLD is typically the original innovator product, and it serves as the benchmark every generic version is measured against for dosage, strength, route of administration, and bioavailability.
This is a narrower and more specific concept than “brand-name drug” or “originator product.” Not every version of an approved drug qualifies as the RLD — the FDA designates one specific product as the standard, and generic applicants must reference that exact designation in their submissions.
Why RLDs Matter in Drug Development and ANDA Submissions
The RLD is the anchor point for an entire generic development program. Bioequivalence studies compare the test product’s pharmacokinetic profile directly against the RLD, and regulatory reviewers expect that comparison to use the correctly designated reference product — not a similar-looking substitute. Using the wrong reference product, or one with unclear provenance, can mean:
- A bioequivalence study that regulators reject outright, regardless of how well it was run
- Delays while a new, correctly sourced RLD batch is identified and procured
- Questions raised during inspection about chain-of-custody documentation
In short, RLD sourcing isn’t a procurement afterthought — it’s a regulatory dependency that sits upstream of the entire development timeline.
The Hidden Difficulty in Sourcing an RLD
Sourcing an RLD sounds simple — buy the brand-name drug — but in practice it’s one of the more quietly difficult procurement tasks in generic drug development, for a few reasons:
Discontinued or hard-to-find products. Some designated RLDs are older products that are no longer widely distributed, making sourcing a genuine search-and-verify exercise rather than a standard purchase.
Authenticity and chain of custody. Regulatory submissions increasingly expect documented proof that the RLD batch used in a study is authentic and traceable — not just “purchased from a pharmacy,” but accompanied by verifiable sourcing documentation.
Batch consistency. Different batches or lots of the same RLD can show meaningful variability. A sourcing partner needs to understand batch selection, not just product identification.
Correct designation matching. Because the FDA designates a specific RLD (not just “any version of this drug”), sourcing teams need to confirm they’re procuring the product that actually matches the Orange Book listing being referenced in the submission.
What to Look for in an RLD Sourcing Partner
A credible RLD sourcing partner should be able to provide, at minimum:
- Confirmed product identity matched against the correct Orange Book RLD designation
- Certificate of Analysis (CoA) and batch documentation for the specific lot supplied
- Chain-of-custody documentation establishing traceability from source to delivery
- Sourcing timeline transparency — realistic lead times, especially for harder-to-find or discontinued products
- Regulatory familiarity — a partner who understands why these details matter for an ANDA submission, not just a general pharmaceutical distributor
How Chemigran Sources and Validates Reference Listed Drugs
Chemigran has spent over three decades sourcing pharmaceutical products across API, RLD, and reference standard categories for clients running bioequivalence and generic development programs. Our approach to RLD sourcing centers on verified product identity, full batch documentation, and transparent chain-of-custody records — the same standard we apply across our broader API and reference standard catalog. Because we work directly with generic developers and regulatory teams, we understand that an RLD isn’t just inventory — it’s a regulatory dependency, and we treat the sourcing process accordingly.
If your development program needs a correctly sourced, fully documented Reference Listed Drug, our team can help identify, verify, and deliver it — including for harder-to-find or discontinued designations.
FAQ
What is the difference between an RLD and a generic drug?
The RLD is the FDA-designated reference product that generic drugs are compared against for bioequivalence. A generic drug is the product being developed to match the RLD’s performance, not the reference itself.
Can a discontinued drug still be used as a comparator RLD?
Yes — the FDA can maintain a discontinued product’s RLD designation, meaning developers may still need to source it even though it’s no longer actively marketed. This is one of the more common sourcing challenges.
What documentation should come with a sourced RLD?
At minimum, a Certificate of Analysis for the specific batch, confirmation the product matches the correct Orange Book designation, and chain-of-custody documentation establishing the product’s authenticity and traceability.
How long does RLD sourcing typically take?
It varies significantly based on how widely available the designated product is — a currently marketed RLD may be sourced quickly, while a discontinued or low-distribution product can take considerably longer to locate and verify.
Ready to source a correctly documented Reference Listed Drug for your development program? Contact the Chemigran team or explore our Reference Listed Drug catalog.
